SCHEMBL21647723

SCHEMBL21647723

O=S(=O)(c1ccccc1)N(c1cccc(Br)c1)S(=O)(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
APOBEC3G Q9HC16 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
VCAM1 P19320 1/20 0.41
MMP2 P08253 1/20 0.41
PTPRC P08575 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PGR P06401 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ESR1 P03372 1/20 0.40
BRD4 O60885 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11576079 0.80 APOBEC3G (0.56) SMN1; SMN2APOBEC3GALDH1A1PKMVCAM1
SCHEMBL16550139 0.79 KMT2A (0.59) APOBEC3GALDH1A1PKMVCAM1PTPRC
SCHEMBL28511190 0.79 CYP3A4 (0.55) APOBEC3GALDH1A1PKMVCAM1PTPRC
SCHEMBL1963814 0.78 MEN1 (0.62) SMN1; SMN2ALDH1A1PKMMEN1KMT2A
SCHEMBL23706376 0.77 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MEN1KMT2APGR
SCHEMBL22441784 0.76 LMNA (0.57) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL8973992 0.76 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21647692 0.75 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1PKMMEN1KMT2A
SCHEMBL21647719 0.74 ESR1 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5731154 0.74 RORC (0.57) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188023-A1 BENZENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2025-06-12 US disclosed
US-12258308-B2 Benzene derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2025-03-25 US disclosed
CN-112513011-B Benzene derivatives 小野药品工业株式会社 2023-06-16 CN disclosed
US-20220089532-A1 BENZENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2022-03-24 US disclosed
US-11261154-B2 Benzene derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2022-03-01 US disclosed
US-20210332009-A1 BENZENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2021-10-28 US disclosed
EP-3831810-A1 BENZENE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2021-06-09 EP disclosed
CN-112513011-A Benzene derivatives 小野药品工业株式会社 2021-03-16 CN disclosed
WO-2020027150-A1 BENZENE DERIVATIVE 小野薬品工業株式会社 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258308-B2 Benzene derivative PMP22, TMBIM6, MYT1 SMN1; SMN2 44/4885APOBEC3G 3051/4885ALDH1A1 1189/4885
US-11261154-B2 Benzene derivative PMP22, TMBIM6, MYT1 SMN1; SMN2 44/4885APOBEC3G 3051/4885ALDH1A1 1189/4885
US-20250188023-A1 BENZENE DERIVATIVE PMP22, TMBIM6, MYT1 SMN1; SMN2 49/4885APOBEC3G 3056/4885ALDH1A1 1203/4885
US-20210332009-A1 BENZENE DERIVATIVE PMP22, TMBIM6, MYT1 SMN1; SMN2 44/4885APOBEC3G 3051/4885ALDH1A1 1189/4885
US-20220089532-A1 BENZENE DERIVATIVE PMP22, TMBIM6, MYT1 SMN1; SMN2 44/4885APOBEC3G 3051/4885ALDH1A1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.